By Yafo Life Sciences
December 26th, 2021 (Shanghai) — We are glad to announce that Hung-Kai Kevin Chen, the Chairman and CEO of Elixiron Immunotherapeutics, has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
If you are interested in listening to the live event, please register at https://biotochina.org/register/
About Elixiron Immunotherapeutics
Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics from phage display and single human B cell cloning platforms, to develop innovative therapies for cancer and immunological diseases. See our Pipeline of therapeutics under development below to learn more about our commitment to bring better, next-generation as well as new first-in-class immunotherapies to patients.
About the speaker
Over the course of his career, he has been committed to advancing the development of breakthrough treatments with particular emphasis on translational medicine. Most recently, Kevin served as Senior VP and Chief Medical Officer of Eusol Biotech, a clinical stage company focused on developing therapeutics for neurological diseases. Prior to Eusol, Kevin served as Director of Translational Medicine at the Development Center for Biotechnology (DCB), Taiwan, where he led an initiative to implement translational medicine strategy across drug development stages. He played a key role in strategic planning and building the immune-oncology portfolio, and led the development of anti-TIM3 and CSF1R inhibitor preclinical candidates. Prior to DCB, Kevin was a Principal Scientist at GSK’s Neuroimmunology Discovery Performance Unit in Shanghai where he led a project team and successfully moved a novel drug discovery project from target identification and validation to lead optimization. He also served on global development teams, leading the biomarker and translational studies for a phase 2 clinical trial. Prior to joining GSK, Kevin was as an Assistant Investigator at the Gladstone Institutes’ Translational Research Center in San Francisco. Kevin actively participated in a multi-million-dollar academia-industry collaborative project with Merck Co.,Inc. for the development of small molecule drugs for treating Alzheimer’s disease.
He is an awardee of the 2020 Part the Cloud-Gates Partnership Grant (1 million USD) and the 2020 National Innovation Award (gold medal). Kevin has authored or co-authored several peer-reviewed publications in leading journals including Cell, Nature Medicine and Nature Communications. Kevin earned his M.D. and Ph.D. from National Yang-Ming University and completed postdoctoral training at Baylor College of Medicine and Howard Hughes Medical Institute at Houston, Texas.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact: